Vivos Therapeutics (NASDAQ: VVOS)
, a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), plans to release its fourth-quarter and full-year financial reports on March 25, 2021, after market close; the numbers will cover the period ending Dec. 31, 2020. The company has scheduled a conference call for 5 p.m. ET the same day. During the call, Vivos executives will discuss the financial report and provide an overview of the company’s 2020 milestones and growth strategy moving forward. Interested parties can access the call by dialing (877) 451-6152; international callers can dial (201) 389-0879; the passcode for the call is 13717735. After the call has concluded, a replay of the call can be accessed until April 8, 2021, by dialing (844) 512-2921 — international callers dial (412) 317-6671; the same passcode will be used for the replay. A live webcast version of the call will also be available, with an online archive of the webcast available on the company’s website for 30 days.
To view the live webcast, visit https://ibn.fm/EdG22
To view the full press release, visit https://ibn.fm/RFY2V
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com
NOTE TO INVESTORS:
The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.